In 1841 Magendi pioneered to measure cerebrospinal fluid pressure using the ''sphygmometer,'' an instrument originally designed for assessment of blood pressure. From then on, it took 110 years before the first intracranial pressure (ICP) monitoring data has been published in 1951, first ever introducing the important key-word of ''monitoring'' in the context of the human brain [1] . From this moment the field of brain monitoring has been growing continuously. Apart from recording of ICP and cerebral perfusion pressure (CPP), modern multimodality brain monitoring comprises several techniques including assessment of brain tissue oxygenation (P br O 2 ), brain metabolism, and cerebral blood flow. Noninvasive approaches are transcranial Doppler (TCD) ultrasonography, EEG monitoring, and near-infrared spectroscopy (NIRS).
Most of the experience in multimodality brain monitoring has been gained from comatose patients after traumatic brain injury, poor grade subarachnoid hemorrhage, or severe stroke. The main objectives of brain monitoring are (1) the detection of ongoing secondary brain injury following the primary insult, (2) guiding therapeutic interventions, and (3) prediction the outcome. Ideally, brain monitoring should prompt a timely and appropriate intervention and should be included in scheduled management protocols. [8] . The most important gap to be filled at the present stage is to establish a clear link from monitoring to management protocols. Proofs (in form of randomized trials) of a closed loop-''patient-monitoring-doctor-protocoloutcome''-are to be delivered. Monitoring ''per-se,'' in the absence of matching management protocols and effective therapies, cannot improve outcome. 3. It seems advisable to choose a multimodal approach in order to acquire a maximum of information (see Fig. 1 ). In some instances, ''a little bit of brain monitoring'' may be more harmful than no monitoring at all. A single cerebral event can be caused by different pathophysiological mechanisms. An increase of ICP for example may be due to cerebral edema or transient hyperemia, each requiring different therapeutic responses. A therapeutic regimen, e.g., infusion of mannitol, based only on the information available from the ICP monitor, may even further aggravate the situation. While no protocols are available what modalities should be used, it seems wise to choose a multimodal approach. Furthermore, failures of sensors are common, the most frequent complication of brain monitoring was found to be device malfunction or dislodgement [9] . On the other hand, rates of hematoma or infections related to brain monitoring were reported between 3% and 5% in a recent study. 4. In many modalities, probes pick up signals very locally. Probe placement therefore is crucial and it has to be kept in mind that thresholds for healthy and unhealthy brain tissue of course vary considerably. 5. Complexity of multimodal monitoring requires specialized and intelligent IT support. Various solutions (CMA Pilot, Edinburgh Browser, ICMPlus) are available and are becoming more popular nowadays. Not all neurocritical care units are ready to use them straightaway.
Modalities and Their Merits
6. Yet, the more complex the monitoring systems, the more the benefit from monitoring will depend on the skills of the clinicians to properly interpret and integrate the gathered information. While adequate training in interpretation seems indispensable, a proper evaluation of the interpretive ability of neurointensivists with respect to brain monitoring has not yet been undertaken. 7. Particularly, the missing link to outcome (commonly caused by a low number of studied cases) is a frequently raised criticism with respect to multimodality brain monitoring. Provided adequate clinicians' ability in data interpretation, a randomized trial on efficacy of brain monitoring, however, always will include testing the efficacy of a therapeutic regimen, employed as a result of the monitoring data. The benefit of monitoring thus will always be interwoven with the progress of therapies and development of new therapeutic standards. It is unrealistic to expect dramatic improvements in the outcome from monitors, especially when they are used to optimize existing therapies and no new therapies are employed [10] .
In the study ''Systemic glucose and brain energy metabolism after subarachnoid hemorrhage,'' Helbok et al. [11] provide a catchy example why monitoring of therapeutic effects of standard, seemingly trivial procedures such as titration of serum glucose may be required. They found that acute reductions in serum glucose, even within the normal ranges, were associated with brain energy metabolic crisis. Thus, a standard intervention, and for instance not alarmingly in the setting of a medical ICU, may severely compromise the acutely brain injured patient. While a link has been established between occurrence of metabolic crisis and outcome [12] , this study, however, arises several questions: What are the underlying pathomechanisms? Is there a ''metabolic penumbra'' in other entities of brain injury? What glucose levels should be targeted for treatment? And ultimately, will an individualized glucose management as suggested by the authors, lead to improved outcome?
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